CCO Practice Guidelines
| CATEGORY |
REGIMEN CODE |
NAME OF DRUGS USED IN THERAPY |
| Core, Restricted CCO |
VINOCISP |
Vinorelbine-Cisplatin |
Non-small Cell (NSCLC) Adjuvant
| CATEGORY |
REGIMEN CODE |
NAME OF DRUGS USED IN THERAPY |
| Core |
CISPETOP-RT |
Cisplatin-Etoposide |
| Core, Not Funded |
VINOCISP-RT |
Vinorelbine-Cisplatin |
| Archive |
CISP-RT |
Cisplatin |
|
CISPVINB |
Cisplatin-Vinblastine |
|
CISPVINB-RT |
Cisplatin-Vinblastine |
|
MIC*NEO |
Mitomycin-Ifosfamide-Cisplatin |
|
MVP*NEO |
Mitomycin-Vinblastine-Cisplatin |
Non-small Cell (NSCLC) - Locally Advanced
| CATEGORY |
REGIMEN CODE |
NAME OF DRUGS USED IN THERAPY |
| Core |
CAV |
Cyclophosphamide-ADRIAMYCIN® (Doxorubicin)-Vincristine |
|
CISPETOP |
Cisplatin-Etoposide |
|
CISPET-RT |
Cisplatin-Etoposide |
|
ETOPCARBO |
Etoposide-Carboplatin |
| Core, Not Funded |
TOPOTECAN |
Topotecan |
| Archive |
CAE |
Cyclophosphamide-ADRIAMYCIN® (Doxorubicin)-Etoposide |
|
CAV-ECARB |
Cyclophosphamide-ADRIAMYCIN® (Doxorubicin)-Vincristine-Etoposide-Carboplatin |
|
CAV-TP |
Cyclophosphamide-ADRIAMYCIN® (Doxorubicin)-Vincristine-Teniposide-PLATINOL® (Cisplatin) |
| | CAVEP-IV
| Cyclophosphamide-ADRIAMYCIN® (Doxorubicin)-Vincristine-Etoposide (intravenous)-PLATINOL® (Cisplatin) | | | CAVEP-PO
| Cyclophosphamide-ADRIAMYCIN® (Doxorubicin)-Vincristine-Etoposide (oral)-PLATINOL® (Cisplatin)
|
|
CEV |
Cyclophosphamide-Epirubicin-Vincristine |
|
CEV-EP |
Cyclophosphamide-Epirubicin-Vincristine-Etoposide-PLATINOL® (Cisplatin) |
| ETOP-PO | Etoposide (oral) |
|
ICARBO-E |
Ifosfamide-Carboplatin-Etoposide |
Small Cell (SCLC)
|
|
Last modified: Thu, Jul 15, 2010